Skip to content
Sign in

NTLA · NASDAQ

Intellia Therapeutics (NTLA) Stock Price & Fundamentals

$322.29−1.32%−$4.31End-of-day price as of Oct 9, 2026

Intellia Therapeutics (NTLA) closed at $322.29 on Oct 9, 2026, down 1.32% from the previous close of $326.60.

Share price, past year

1Y +7.89%

52-week range $292.36 – $341.16. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$322.29
Sep 30, 2026$318.45
Aug 31, 2026$337.25
Jul 31, 2026$340.39
Jun 30, 2026$321.53
May 29, 2026$310.70
Apr 30, 2026$326.57
Mar 31, 2026$316.36
Feb 27, 2026$318.04
Jan 30, 2026$313.36
Dec 31, 2025$305.44
Nov 28, 2025$316.75
Oct 31, 2025$303.03

Key statistics

Market cap
$45.13B
P/E (TTM)
—
EPS (TTM)
−$3.34
Revenue (TTM)
$59.51M
Net income (TTM)
−$399.98M
Shares outstanding
140M
Dividend yield
—
52-week range
$292.36 – $341.16

Intellia Therapeutics's market cap is $45.13B, based on a share price of $322.29 and 140M shares outstanding as of Jun 30, 2026.

Financials

Intellia Therapeutics reported revenue of $67.67M for fiscal 2025, up 16.92% from fiscal 2024.

Intellia Therapeutics reported a net loss of $412.69M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Intellia Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$67.67M+16.9%−$412.69M−609.9%−$3.81−$395.87M
FY2024ended Dec 31, 2024$57.88M+59.6%−$519.02M−896.8%−$5.25−$354.66M
FY2023ended Dec 31, 2023$36.28M−30.4%−$481.19M−1,326.5%−$5.42−$408.07M
FY2022ended Dec 31, 2022$52.12M+57.7%−$474.19M−909.8%−$6.16−$346.85M
FY2021ended Dec 31, 2021$33.05M−43.0%−$267.89M−810.5%−$3.78−$237.79M
FY2020ended Dec 31, 2020$57.99M+34.6%−$134.23M−231.5%−$2.40−$53.50M
FY2019ended Dec 31, 2019$43.10M+41.6%−$474.19M−1,100.1%−$2.11−$110.03M
FY2018ended Dec 31, 2018$30.43M+16.5%−$85.34M−280.4%−$1.98−$67.62M
FY2017ended Dec 31, 2017$26.12M+58.5%−$67.54M−258.6%−$1.88−$75.37M
FY2016ended Dec 31, 2016$16.48M—−$31.63M−192.0%−$1.42$29.94M
Intellia Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$7.66M−$106.63M−$0.80
Q1 FY2026ended Mar 31, 2026$15.05M−$96.23M−$0.81
Q4 FY2025ended Dec 31, 2025$23.02M−$95.79M−$0.81
Q3 FY2025ended Sep 30, 2025$13.78M−$101.32M−$0.92
Q2 FY2025ended Jun 30, 2025$14.25M−$101.26M−$0.98
Q1 FY2025ended Mar 31, 2025$16.63M−$114.33M−$1.10
Q4 FY2024ended Dec 31, 2024$12.87M−$128.90M−$1.27
Q3 FY2024ended Sep 30, 2024$9.11M−$135.71M−$1.34

Company profile

Name
Intellia Therapeutics, Inc.
Ticker
NTLA
Exchange
NASDAQ
Industry (SEC SIC)
In Vitro & In Vivo Diagnostic Substances
Headquarters
40 Erie Street, Suite 130, Cambridge, MA 02139
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001652130

Recent SEC filings

Frequently asked questions

What is Intellia Therapeutics's stock price?

Intellia Therapeutics (NTLA) closed at $322.29 on Oct 9, 2026, down 1.32% from the previous close of $326.60.

What is Intellia Therapeutics's market cap?

Intellia Therapeutics's market cap is $45.13B, based on a share price of $322.29 and 140M shares outstanding as of Jun 30, 2026.

How much revenue does Intellia Therapeutics make?

Intellia Therapeutics reported revenue of $67.67M for fiscal 2025, up 16.92% from fiscal 2024.

Does Intellia Therapeutics pay a dividend?

Intellia Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Intellia Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures